Efficacy and Safety of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist Once Weekly for Weight Management: A Randomised, Double-Blind, Placebo-Controlled Trial
Overall, the results of the SURPASS-3 substudy showed a positive correlation with change in baseline LFC and changes in A1c, body weight, VAT and ASAT
Gastrointestinal side effects: the most common challenge Nausea affects roughly 20% of patients
A secondary analysis of SURMOUNT data revealed that participants with baseline triglyceride levels above 150 mg/dL saw the most dramatic improvements, with some experiencing 30% or greater reductions
In an adult over 65 who already has reduced baseline muscle mass, impaired anabolic response to protein, and a higher fracture risk, additional muscle and bone loss is not a minor side effect